Osteonecrosis of the jaw during biyearly treatment with zoledronic acid for aromatase inhibitor associated bone loss in early breast cancer: A literature review

Osteonecrosis of the jaw (ONJ) is one of the most relevant and specific complication of biphosphonates. ONJ in patients receiving zoledronic acid every 3 to 4 weeks is frequently described, but the ONJ biyearly regimen used to reduce aromatase inhibitor associated bone loss (AIBL), is rarely reporte...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Bone Oncol
Autors principals: Kourie, Hampig Raphael, Antoun, Joelle, El Rassy, Elie, Rassy, Marc, Sader-Ghorra, Claude, Kattan, Joseph
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2015
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648993/
https://ncbi.nlm.nih.gov/pubmed/26587372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2015.09.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars